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as a functional RTK/GPCR hybrid, which integrates the 
kinase signaling with the IGF-1R canonical GPCR charac-
teristics. The contradictions to the classical IGF-1R signal-
ing concept as well as the design of anti-IGF-1R therapeu-
tics treatment are considered in the light of this paradigm 
shift and we advocate recognition of IGF-1R as a valid tar-
get for cancer treatment.
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Abbreviations
aa  Amino acid residues
A-loop  Activation loop
ATP  Adenosine triphosphate
CH2  Collagen homology 2 domain
C-terminal  Carboxyl terminal
cAMP  Cyclic adenosine monophosphate
CReB  cAMP response element binding-protein
eCM  extra-cellular matrix
eGFR  epidermal growth factor receptor
eRK  extracellular-related kinase
eS  ewing sarcoma
GDP  Guanosine diphosphate
GSK 3β  Glycogen synthase kinase
GTP  Guanosine triphosphate
G proteins  Guanine nucleotide binding-proteins
GPCRs  G-protein coupled receptors
Grb2  Growth factor receptor bound protein
GRKs  GPCR-related kinases
IGF  Insulin-like growth factor
IGFBP  Insulin-like growth factor binding-protein
IGF-1R  Insulin-like growth factor-type 1 receptor
IR  Insulin receptor
IRR  Insulin receptor-related receptor
Abstract The insulin-like growth factor type 1 receptor 
(IGF-1R) plays a key role in the development and progres-
sion of cancer; however, therapeutics targeting it have had 
disappointing results in the clinic. As a receptor tyrosine 
kinase (RTK), IGF-1R is traditionally described as an ON/
OFF system, with ligand stabilizing the ON state and exclu-
sive kinase-dependent signaling activation. Newly added to 
the traditional model, ubiquitin-mediated receptor down-
regulation and degradation was originally described as a 
response to ligand/receptor interaction and thus inseparable 
from kinase signaling activation. Yet, the classical model 
has proven over-simplified and insufficient to explain 
experimental evidence accumulated over the last decade, 
including kinase-independent signaling, unbalanced signal-
ing, or dissociation between signaling and receptor down-
regulation. Based on the recent findings that IGF-1R “bor-
rows” components of G-protein coupled receptor (GPCR) 
signaling, including β-arrestins and G-protein-related 
kinases, we discuss the emerging paradigm for the IGF-1R 
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IRS  Insulin receptor substrate
MAPK  Mitogen-activated protein kinase
Mdm2  Mouse double minute 2 homolog
MeK  Mitogen-activated protein kinase
N-terminal  Amino terminal
PDK  3-Phosphoinositide-dependent protein kinase
PH  Pleckstrin homology
PTB  Phosphotyrosine binding domain
PI3K  Phosphoinositol 3 kinase
PIP3  Phosphoinositol triphosphate
PPP  Picropodophyllin
RTKs  Receptor tyrosine kinases
TK  Tyrosine kinase
TKI  Tyrosine kinase inhibitor
SAPK  Stress-activated protein kinase
SH2/3  Src homology 2/3 domain
Shc  SH2 domain-containing-protein
SOCS  Suppressor of cytokine signaling
Sos  Son of sevenless
SRF  Serum responsive factor
TKI  Tyrosine kinase inhibitor
Introduction
Transmission of extracellular signals across the plasma 
membrane by receptors is a fundamental, evolutionary con-
served cellular process. These signals are in part generated 
by specialized plasma membrane receptors, grouped into 
different families based on their specific structural charac-
teristics. Although different receptor families utilize com-
mon intracellular signaling-proteins and activate common 
signaling pathways, each cell surface receptor family leads 
to specific biological outcomes in the cell [1].
The receptor tyrosine kinases (RTKs) represent one major 
cell surface receptor family, containing around 60 members, 
subdivided into at least 13 receptor families [2, 3]. The RTKs 
are defined by the presence of an intracellular tyrosine kinase 
domain and typically a large glycosylated extracellular 
ligand binding domain, separated by a single transmembrane 
pass [4]. Traditionally defined by their ligands and hence 
ligand binding domains, the cytoplasmic kinase regions, jux-
tamembrane domain and carboxyl (C)-terminal tail also dif-
fer significantly among the individual receptors.
The canonical, binary model still in use today, describes 
the RTKs as having an OFF/ON mechanism. The agonist 
stabilizes the “ON” state through autophosphorylation of 
tyrosine residues within the kinase domain, followed by 
exponential increase in its kinase activity and subsequent 
activation of the intra-cellular signaling pathways [1]. In 
most cases, the ligand-induced activation of the kinase 
domain is mediated by receptor oligomerization (for 
reviews, see [4–6]). This event favors interactions between 
cytoplasmic kinase-partners and induces kinase transacti-
vation. Dimerization can take place between two identical 
receptors (homodimerization), between different members 
of the same receptor family, or, in some cases, between a 
receptor and an accessory protein (heterodimerization) [6–
9]. How ligands bind to receptors and induce oligomeriza-
tion seems specific for each class of RTK [7, 10].
Over the last decades, RTKs have received particular 
attention, not only as essential regulators of normal cel-
lular processes but also as key factors involved in the 
development and progression of human cancers. From the 
first discovery of a mutated RTK in cancer in 1984 [11], 
a huge amount of information about aberrant RTK signal-
ing in cancer has built up, leading to incontestable recog-
nition of various forms of RTK hyper-activation in cancer: 
gene amplification, overexpression, mutation, or autocrine 
growth factor loops that are responsible for the cancer-pro-
moting potential of RTKs [12].
Among RTKs, the insulin-like growth factor type-1 recep-
tor (IGF-1R) is one of the most important players in cancer 
development. The fundamental evidence for this is the dem-
onstration that IGF-1R knock-out mouse embryonic cells are 
refractory to transformation by several oncogenes, viruses, 
or over-expression of other RTKs [13]. Subsequently, IGF-
1R and its natural ligands were demonstrated to regulate 
multiple cellular functions essential for the malignant phe-
notype including cellular proliferation, survival, anchorage-
independent growth, tumor neovascularization, migration, 
invasion, and metastasis [14–17]. Confirming this critical 
role, in preclinical settings, a large amount of experimental 
data clearly demonstrates that inhibition of IGF-1R would be 
beneficial for cancer treatment [18–24]. In vivo and in vitro 
studies using IGF-1R antibodies, small molecule inhibitors, 
and antisense technology have shown that IGF-1R is func-
tionally essential for tumor cell growth and proliferation in 
most if not all forms of cancer [23, 25–28]. On the other 
hand, in clinical settings, no clear mechanism of aberrant 
IGF-1R could be recognized: IGF-1 or IGF-1R over-expres-
sion is not a general rule [17, 29], the receptor does not show 
intrinsic receptor abnormalities [30], and therefore other 
regulatory pathways and quantitative changes are likely to be 
involved and have to be considered.
This review will follow the development of our under-
standing of IGF-1R signaling and relate it to the models 
considered when different IGF-1R-targeting strategies are 
designed, in particular with regards to cancer therapy.
Something old: classical signaling pathways 
through IGF‑1R phosphorylation
The IGF family includes ligands, receptors, and IGF-bind-
ing-proteins (IGFBPs). Classically, there are three ligands 
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(insulin, IGF-1, and IGF-2), three cell surface receptors 
[insulin receptor (IR), IGF-1R, and IGF-2R] and at least 
seven IGFBPs modulating the biological activity of the 
growth factors [31–33].
Besides these archetypal members, more recent work 
has identified other proteins as potential members of the 
IGF family: the antimicrobial peptide LL-37 as ligand [34], 
the orphan insulin-receptor-related receptor (IRR) [35], the 
insulin-IGF-1R hybrid receptor [36, 37], and a growing 
number of IGFBPs [38].
Unlike other RTKs, the IR and IGF-1R exist as pre-
formed dimers (Fig. 1). The IGF-1R has a membrane 
spanning tetrameric structure. It is synthesized as a single 
chain α-β pro-receptor which is processed by proteolysis 
and glycosylation [33, 39]. In mature, functional form, it 
consists of two identical extra cellular α-subunits and two 
identical β-subunits, all linked by disulfide bridges. The 
β-chain contains an extra cellular domain, a transmembrane 
domain, and a kinase-containing intracellular domain [39, 
40] (Fig. 1). On the whole, there is high homology (70 %) 
between the IGF-1R and the IR amino acid sequences [40, 
41].
The α-subunit contains 710 amino acids (aa 1–710) 
and has in its structure two homologous domains (L1 and 
L2) separated by a cysteine-rich domain (48 %) contain-
ing 25 or 27 cysteines, in three repeating units [33]. The 
cysteine-rich domain (aa 148–302) is responsible for the 
ligand binding and is also conserved in the IR [42–46]. The 
spanning plasma membrane β-subunit contains 627 amino 
acid residues (aa 711–1337), distributed among the extra 
Fig. 1  IGF-1R structure–
function relationship. The map 
of the IGF-1R is annotated with 
the numbered aa residues. The 
key residues as determining 
binding of substrates/adap-
tor proteins are highlighted 
and linked with the binding 
partners. The known sites of 
posttranslational modifications 
(PTMs) within the β-subunit are 
indicated
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cellular domain (196 aa), the transmembrane domain (aa 
906–929), and the intracellular portion of the β-subunit, 
which itself is subdivided into three domains: a juxtamem-
brane domain, the tyrosine kinase (TK) domain, and C-ter-
minal domain/tail. The juxtamembrane domain contains an 
NPXY motif, which may be important for receptor inter-
nalization [47–50]. The catalytic region of IGF-1R contains 
the ATP binding motif (GXGXXG) at positions 976–981, 
and a catalytic lysine in position 1003, which is critical for 
the Mg-ATP binding [51]. within the TK domain, a clus-
ter of three tyrosines, located at positions 1131, 1135, and 
1136, is critical for receptor autophosphorylation [41]. The 
C-terminus of the IGF-1R (roughly the last 100 amino 
acids) contains several regulatory elements essential for 
IGF-1R function [52] (Table 1; Fig. 1).
The TK domain is highly homologous to that of the IR 
(84 %), the juxtamembrane domain shares 61 % of homol-
ogy with the IR, whereas the C-terminal domain shares 
only 44 % [40]. Despite this high degree of homology, it is 
largely accepted that the two receptors have distinct biolog-
ical roles. The IR is known to be a key regulator of physi-
ological processes such as glucose transport and biosynthe-
sis of glycogen and fat [53], whereas the IGF-1R is a potent 
regulator of cell growth, proliferation, and differentiation 
[54, 55]. The structure–function relationship of the IGF-1R 
has been extensively investigated, with mutational analysis 
revealing residues crucial for the binding of signaling or 
adaptor proteins (Table 1; Fig. 1) or particular downstream 
bioactivities (Table 1).
IGF-1R tyrosine kinase activation
According to the classical model, IGF-1/2 binding induces 
a conformational change in the preformed dimeric recep-
tor, leading to activation of the RTK [6]. In the unphos-
phorylated state, the receptor catalytic activity is very low 
Table 1  IGF-1R structure–
function relationship
The key residues for 
posttranslational modifications, 
protein–protein interaction 
and their functional outcome 
as determined by mutation-
analysis are summarized
K kinase activity,  
I internalisation, M mitogenic,  
T transforming, A anti-
apoptotic, M/I migration/
invasion, Su Sumoylated 
residue, Ub ubiquitinated 
residue, pY phosphotyrosine,  
pS phosphoserine
Residues Binding partners Functions
v922 M [267]
Y943 I [50]
Y950 IRS-1/2/3/4 [268–271], Shc [268, 269, 
272], CrkII, CrkL [82, 273, 274]
I [49, 50], M, T [89, 275–278], pY
Y957 I [50]
Kinase domain 969–1236 RACK1 [87], vav [80], vav3 [81], 
p125FAK [83]
976–981 ATP binding site, A [89]
K1003 A, M, T, K [89, 279]
K1025, K1100, K1120 Su [151]
K1081 [280]
G1125 K [281]
K1138, K1141 Ub [141]
Y1131, Y1135, Y1136 Auto-phosphorylation, M, T, K [89, 
234, 276, 282, 283], pY
w1173 A, T [284]
Y1221 K [276]
1229–1245 Grb10 [78]
S1248 RACK1 [88], βarr1 [124, 134] pS
Y1250 T [128], M/I, A [89, 276, 285]
Y1251 I [286], K [276], A, T [89]
S1252 pS, I [280]
S1272 14.3.3 [287]
S1280–S1283 14.3.3 [268, 288, 289] T [290, 291]
S1291 βarr1 [124, 134] pS
H1293–K1294 A [89, 292]
F1310 A [277]
Y1316 Grb10 [79], p85 [293], SHP2 [84,  
145], PI3K [63]
[89, 292]
Undetermined p38, JNK [294], TIMP2 [295],  
SOCS1/2 [86], SOCS3 [296],  
p55γ [297], JAK1/2 [298]
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due to the inhibitory conformation of a specific domain in 
the kinase region, which interferes with ATP-binding and 
tyrosine phosphorylation. This domain, known as the acti-
vation loop (A-loop), behaves as a pseudosubstrate that 
blocks the active site [56]. The A-loop contains the criti-
cal tyrosine (Tyr) residues 1131, 1135, and 1136 and the 
activation of intrinsic protein kinase activity results in the 
autophosphorylation of them [56] (Fig. 1). Tyr 1135 (being 
the first tyrosine to be phosphorylated) in the A-loop is 
bound in cis position in the active site, thus preventing 
substrate access while simultaneously occluding the ATP 
binding site. The kinase activity is at a low basal level, 
but sufficient to induce trans-autophosphorylation, once 
stimulated. After ligand binding, the three tyrosines of the 
A-loop are trans-phosphorylated by the dimeric subunit 
partner. Phosphorylation of Tyr 1135 and Tyr 1131 desta-
bilizes the auto-inhibitory conformation of the A-loop, 
whereas phosphorylation of Tyr 1136 and, to a lesser 
extent, Tyr 1135 stabilizes the catalytically optimized con-
formation of it [56]. Autophosphorylation of Tyr 1135 is 
necessary but not sufficient to destabilize the autoinhibi-
tory A-loop conformation; full destabilization also requires 
autophosphorylation of Tyr 1131. Autophosphorylation 
also occurs outside the kinase domain and creates dock-
ing sites for downstream signal transduction molecules. 
According to the classical model, the two main down-
stream signaling pathways activated by IGF-1R kinase are 
the MAPK and PI3K pathways (Fig. 2).
Intracellular substrates of the IGF-1R tyrosine kinase
The docking sites outside the kinase domain bind signal 
transduction molecules and adaptor proteins to activate 
downstream signaling pathways. One important docking 
site of the IGF-1R to a substrate is the NPXY950 motif 
in the juxtamembrane domain. This motif is recognized 
by the phosphotyrosine binding (PTB) domain that the 
insulin receptor substrates (IRSs) and the src homology 
2 (SH2)-containing-protein (Shc) possess (Figs. 1, 2). 
extensive mutation analysis exposed the specific residues 
involved in binding these substrates as indicated in Fig. 1 
and Table 1.
After phosphorylation of the tyrosine residues of the 
β-subunit of the IGF-1R, the first molecule that reaches 
full binding in 1–2 min is the IRSs. The IRS protein fam-
ily consists of four proteins from IRS1 to IRS4. Among 
them, IRS1 and IRS2 are well known to play important 
roles in mediating metabolic effects of the IGFs as well as 
their cell growth and differentiation activities. each IRS 
possesses high homology regions: a pleckstrin homology 
domain (PH) and a PTB domain at the N-terminal region. 
These regions are thought to be important for interaction 
with cell surface receptors. The C-terminal region of IRS 
proteins is poorly conserved, suggesting that this region 
mediates the different biological activities of each IRS. 
It also has a C-terminal domain with multiple potential 
phosphorylation sites (more than 20 in IRS1/2/4) that 
interact with high affinity to SH2 domain-containing-
proteins in a manner dependent on the specific phospho-
tyrosine motif (YXXX) involved [57]. The SH2 domain-
containing-proteins include a p85 regulatory subunit of 
phosphatidylinositol 3-kinase (PI3K) class I, growth-fac-
tor-receptor-bound protein 2 (Grb2), SH-PTP2 (a tyros-
ine phosphatase), and other adaptor proteins like Crk and 
Nck. IRS1, as a docking-protein, has been involved in 
interactions with multiple molecules secondary to IGF-
1R activation, and among them β1 integrins seem to have 
an important role in cell adhesion to laminin after IGF-1 
stimulation [58]. In addition, a recent study described 
that IRSs form high-molecular-mass complexes with a 
variety of proteins in a phospho-tyrosine-independent 
manner and modulate their availability to the IGF-1R 
[59, 60].
The second major pathway is through Shc, which 
reaches its maximal phosphorylation within 5–10 min of 
IGF-1R stimulation. Shc has been shown to consist of four 
unique members, ShcA, B, C, and D, and multiple splic-
ing isoforms [61]. In general, Shc proteins possess a PTB 
domain at the N-terminal region and a SH2 domain at the 
C-terminal region. Between the PTB domain and SH2 
domain, there are three tyrosine residues, possibly phos-
phorylated by IGF-1R, involved in Grb2 recruitment.
Fig. 2  IGF-1R kinase-dependent signaling pathways. IGF-1 (or IGF-
2) binding to the IGF-1R promotes intrinsic tyrosine kinase activity 
and auto-phosphorylation. Activated receptor can recruit and phos-
phorylate substrates such as IRS and Shc. Tyrosine phosphorylation 
of IRS and Shc proteins leads to binding of signaling molecules such 
as Grb2 and PI 3-kinase. These associations induce downstream sign-
aling activation, primarily through the MAPK and PI3K pathways 
coordinating downstream IGFs bioactivities
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PI 3-kinase pathway
One of the downstream pathways activated by the IGF-1R 
involves IRS interaction with a p85 regulatory subunit of 
PI3K class I, leading to activation of the catalytic subunit 
p110 of PI3K and inducing phospholipid products activat-
ing the downstream signaling pathway [62].
It has also been shown that tyrosine phosphorylation 
of the IGF-1R (Y1316XXM) can also induce direct bind-
ing of PI3K to the cytoplasmic region of the receptor [63] 
(Figs. 1, 2).
One of the main functions of PI3K is to synthesize the 
second messenger phosphatidyl inositol (3, 4, 5) triphos-
phate (PIP3) at the inner side of the membrane. These 
phospholipids function as ligands for recruiting PH 
domain-containing-proteins to the inner surface of the 
cell membrane [39]. The Akt/PKB serine threonine kinase 
interacts with these phospholipids causing its translocation 
to the inner membrane and activation by the 3-phosphoi-
nositide-dependent protein kinases (PDKs) located around 
the membrane. IGFs-mediated activation of the PI3K path-
way induces phosphorylation of the Thr308 and Ser473 
residues on Akt and activates this kinase [64, 65]. Active 
Akt in turn phosphorylates and inhibits several pro-apop-
totic proteins such as Bad [66] and caspase 9 [67], plus 
at least three other Akt effectors: the survival transcrip-
tion factor cyclic AMP response element binding-protein 
(CReB), the pro-apoptotic effector protein glycogen syn-
thase kinase-3β (GSK-3β), and the winged-helix family 
of forkhead transcription factors FKHRL1, FKHR, and 
AFX. Akt activation can also induce stimulation of mTOR 
that will lead to phosphorylation of the 40S ribosomal S6 
protein by the p70S6 kinase, thereby enabling efficient 
translation of 5′ terminal oligopyrimidine tract (5′TOP) 
mRNA [68]. This class of mRNA is critically involved in 
the control of the protein synthesis machinery regulating 
the transition from G0 to G1 of the cell cycle. Activated 
mTOR can also induce phosphorylation of eukaryotic ini-
tiation factor 4e (eIF-4e) binding-protein (4e-BP), thus 
regulating cell cycle proteins like cyclin D1 [69]. mTOR 
is also involved in activation of matrix metallo protein-
ase (MMP)2 with effects on cell migration and metastasis 
potential [70]. Another effect of Akt activation is phos-
phorylation of Mdm2 on serine 166 and serine 186. Phos-
phorylation on these sites is necessary for translocation of 
Mdm2 from the cytoplasm into the nucleus, where Mdm2 
decreases p53 transcriptional activity and hence dimin-
ishes cellular levels of p53 [71].
MAP kinase pathway
The second major pathway is mediated by tyros-
ine-phosphorylated IRSs or Shc through another 
SH2-domain-containing signaling molecule, Grb2 
(Figs. 1, 2). Grb2 is an adapter protein which possesses 
one SH2 and two SH3 domains. Grb2 can be activated 
by binding directly to phosphorylated IRS or Shc via its 
SH2 domain, while the SH3 domains interact with son of 
sevenless (Sos), a guanine nucleotide exchange protein. 
Sos stimulates the release of GDP and subsequent bind-
ing of GTP to the membrane-bound, low-molecular-mass 
GTP-binding-protein Ras. GTP-bound Ras interacts with 
and translocates the serine/threonine protein kinase Raf 
to the plasma membrane, where Raf becomes activated. 
Activated Raf phosphorylates and activates the dual speci-
ficity mitogen-activated protein kinase (MAPK) MeK, 
which in turn stimulates the eRK subset of MAPKs: 
extracellular-related kinase (eRK)1 and eRK2. eRK1/2 
are translocated into the nucleus where they are involved 
in spindle formation. eRK also mediates transcriptional 
induction of the cyclin D1 gene, stimulating phosphoryla-
tion of the pRb protein and release of the e2F-1 transcrip-
tion factor [72]. The free e2F-1 can activate in its turn the 
transcription of p14ARF [73]. ARF was shown to inhibit 
the p53-Mdm2 association that maintains p53 in its inac-
tive form [74]. In its turn, p53 can directly interfere with 
the Ras/MAPK cascade by inactivating eRK2/MAPK via 
caspase-mediated cleavage [75]. One of the other sub-
strates of MAPK is p90Rsk. Both MAPK and p90Rsk 
translocate to the nucleus after phosphorylation, where 
they phosphorylate and activate transcription factors such 
as serum-responsive factor (SRF), T cell-specific tran-
scription factor, and CReB, and, thus, alter gene expres-
sion. In the cytoplasm, MAPK regulates microtubule 
dynamics by phosphorylating microtubule-associated pro-
teins. By regulating microtubule networks, MAPK regu-
lates the CyclinB/Cdc2 complex: Cyclin B phosphoryla-
tion by MAPK is important for the translocation of the 
complex to the nucleus where it is activated by CDC 25C 
[76, 77].
Other downstream signaling pathways
Previous studies to identify potential substrates of the IGF-
1R and/or interactions with the receptor after its activa-
tion have revealed several additional possible downstream 
signaling molecules. One of these, Grb10, is a member of 
a super family of adaptor proteins, sharing a common over-
all structure, including an N-terminal region harboring a 
conserved proline-rich motif, a central PH domain, and a 
C-terminal SH2 domain. Ligand activation of the IGF-1R 
involves the Grb10 adaptor protein, which probably binds 
to autophosphorylated tyrosine residues located between 
amino acids 1229 and 1245 of IGF-1R [78] or tyrosine 
1316 [79]. Activated Grb10 interacts with neuronal pre-
cursor cell-expressed developmentally downregulated 4 
2409New paradigm for IGF-1R signaling
1 3
(Nedd4), and by doing this it has an important role in ubiq-
uitination of the IGF-1R. Other substrates of the IGF-1R 
tyrosine kinase include the guanine nucleotide exchange 
factors vav [80] and vav3 [81], the adapters CrkII and CrkL 
[82], and focal adhesion kinase (FAK) [83]. Aside from 
IRS proteins, IGF-1R has been reported to interact in vitro 
and/or in vivo with numerous molecules, including Syp 
[39], GTPase-activating-protein [84], C-terminal Src kinase 
[85], and suppressor of cytokine signaling (SOCS)2 [86]. 
The IGF-1R can also activate the stress-activated protein 
kinases (SAPKs) including p38 and Jun N terminal kinase 
(JNK), a pathway associated with regulation of DNA dam-
age responses and cell survival. It has been shown that 
RACK1, a small molecule that was identified as an IGF-
1R interacting protein using a yeast two-hybrid interaction 
trap, regulates IGF-1R signaling and interaction of the IGF-
1R with integrin signaling [87–89]. However, information 
regarding the roles of many of these molecules in IGF-1R 
signaling and biological functions is currently limited.
The classical IGF-1R signaling cascades are more com-
plex, and they have been described in great detail in some 
dedicated reviews [1, 23, 33, 37, 41, 90–94].
Something new: posttranslational modification 
of IGF‑1R controlling IGF‑1R expression and function
Receptor internalization and signal attenuation
Owing to the presence of an intracellular tyrosine kinase 
domain, IGF-1R is classified as an RTK, and accordingly 
phosphorylation was considered to be the central process 
governing IGF-1R signaling [94, 95]. However, during the 
last decade, several laboratories have been investigating the 
mechanisms controlling the subsequent receptor downregu-
lation and signaling desensitization. In this context, other 
posttranslational modifications including dephosphoryla-
tion, serine phosphorylation, ubiquitination, and sumoyla-
tion are increasingly recognized as modulating receptor 
levels and function.
Many cell surface receptors undergo endocytosis, being 
incorporated into clathrin- [96] or caveolin-coated vesicles. 
Some receptors are internalized constitutively and recycled 
(e.g., the transferrin receptor); however, with most RTKs 
and G-protein-coupled receptors (GPCRs), internalization 
is triggered by ligand binding [97, 98]. Ligand-activated 
receptors are normally downregulated by internalization 
[99–101], allowing the cells to return to an unstimulated, 
basal state. This internalization is considered to occur 
only for phosphorylated receptors [99–101], and is thus 
ligand-dependent.
Clathrin- or caveolin-mediated internalization then fol-
lows a process through early endosomes to late endosomes, 
during which decisions regarding fate of the proteins are 
made: whether to recycle or degrade. early endosomes are 
mildly acidic, allowing detachment of the ligand and hence 
attenuation of the signal [102, 103]. If the receptor is to be 
degraded, it will progress to the highly acidic, hydrolase-
containing lysosomal compartments. Internalization of a 
receptor does not necessarily mean immediate cessation of 
the signal followed by receptor degradation. This ligand-
mediated endocytosis appears to have a double function: 
although subsequently attenuating the signal from activated 
receptors, it is also facilitating the interaction between the 
internalized receptor and the downstream signaling mol-
ecules [103]. For example, signaling through the eGFR is 
maintained in endosomal compartments and determines the 
longevity of the signaling [104, 105].
The ubiquitin pathway is a regulatory system for endo-
cytosis [99–101, 106], and RTKs are well recognized as 
targets of ubiquitination [107]. Ubiquitination is the cova-
lent attachment of the 7-kDa ubiquitin polypeptide to lysine 
residues on target proteins through the sequential actions of 
e1, e2, and e3 ligase enzymes [108, 109]. e1 and e2 work 
to load the e3 ligase with the ubiquitin, while e3 trans-
fers the ubiquitin to the target protein. The e3 provides the 
specificity for the substrate, binding directly or through 
adaptor proteins. Ubiquitination can either be mono- (sin-
gle ubiquitin moiety) or poly- (where chains of ubiquitin 
are added). Proteins can be multi-ubiquitinated (at multiple 
lysine residues) and polyubiquitination can be straight or 
branched type, depending on which of the lysine residues 
within ubiquitin the subsequent ubiquitin is attached [101, 
110–112]. The type of ubiquitination is increasingly being 
recognized as determining the fate of the substrate protein 
[113]. Old or damaged cytosolic proteins are labeled with 
a polyubiquitin chain, which is recognized by the protea-
some, multi-subunit proteolytic enzymes situated in the 
cytoplasm.
In addition to the degradation of cytosolic proteins, 
ubiquitin is also implicated in the internalization and degra-
dation of plasma membrane proteins. In mammalian cells, 
a number of membrane proteins which are ubiquitinated 
are degraded through both the proteasome and lysoso-
mal pathways [100], including the IGF-1R [114–117] and 
other RTKs [118, 119]. In some cases (e.g., the RTK Met), 
cytoplasmic fragments are cleaved from the receptor and 
degraded by the proteasome, in a complementary mecha-
nism to lysosomal degradation [119].
IGF-1R internalization, recycling, and degradation
The IGF-1R has been shown to be ubiquitinated [116, 117, 
120] and internalized, through both clathrin and caveolin 
routes, in a ligand-dependent manner [116, 117, 120, 121]. 
Ubiquitination of the IGF-1R occurs prior to entry into 
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endocytotic vesicles [120]. IGF-1R internalization reaches 
an apparent plateau after 20 min at 37 °C in cultured hip-
pocampal neurons, while half-maximal IGF-1R inter-
nalization was obtained after 5 min at 37 °C in NIH-3T3 
fibroblasts [122]. After internalization, some receptors are 
sorted for recycling to the cell surface. In activated T lym-
phocytes, internalization of the IGF-1R from the cell mem-
brane was accompanied by a reduction in its mRNA. This 
was followed by re-expression of IGF-1R on the cell sur-
face and an increase in IGF-1R mRNA levels in the cyto-
plasm, reaching levels higher than those initially recorded. 
However, a slower increase in the mRNA levels indicated 
that the earlier recovery of IGF-1R results from recep-
tor recycling, followed by de novo synthesis [123]. There 
are certainly internal routes where the IGF-1R is recycled 
back to the cell surface and where this balance between 
recycling and degradation can be manipulated [124]. After 
internalization, IGF-1R degradation is mediated by both 
the proteasome and lysosomal pathways or recycled to the 
plasma membrane [100, 114, 116, 117, 120], although the 
relative roles of each are not clear.
A key question is: what is the downregulation signal 
for IGF-1R? To answer this question, at least two mod-
els have emerged during the last decade: one postulating 
internalization by a tyrosine-based motif and another by an 
ubiquitin-based motif. However, these two are not mutu-
ally exclusive, with phospho-tyrosine motifs potentially 
modulating ubiquitination and hence mediating receptor 
internalization.
Tyrosine motif-based downregulation model
The ligand-activated receptors are targeted to clathrin-
coated membrane invaginations [125], a process mediated 
by a specific internalization signal situated within cytoplas-
mic domain of the receptor [100]. There is evidence that 
internalization signals have a tyrosine-based motif usually 
located within the juxtamembrane region of the recep-
tor [126, 127]. The human IGF-1R contains three tyros-
ine residues in the juxtamembrane region [50] that may be 
involved in internalization. However, contradictory results 
have been reported regarding the role of these tyrosine-
based motifs as internalization signals. Prager et al. [50] 
demonstrated that the NPXY motif in IGF-1R is impor-
tant for receptor internalization, whereas Miura et al. [128] 
demonstrated that tyrosine 1250 within the IGF-1R tail is 
the functional tyrosine-based internalization signal (Fig. 1).
Ubiquitin motif-based downregulation model
Degradation of the IGF-1R by a proteasome mediated route 
was originally described by Sepp-Lorenzino et al. [114] to 
explain the mechanism of Herbymicin A-induced IGF-1R 
downregulation. Herbymicin A was demonstrated to only 
degrade IGF-1R in the presence of functional ubiquitin e1 
ligase activity, and its action was prevented by proteasome 
inhibitors while being insensitive to lysosomal inhibitors. 
Since then, the IGF-1R has been demonstrated to be a sub-
strate of three e3 ubiquitin ligases: Mdm2 [116], Nedd4 
[120], and c-Cbl [117].
After Grb10 recognition as an IGF-1R interacting part-
ner and negative regulator of IGF-1 signaling [78, 129], a 
yeast two-hybrid screen subsequently identified Grb10 as a 
binding partner of the Nedd4 e3 ligase [130]. Grb10 over-
expression increased ligand-dependent IGF-1R ubiquitina-
tion, receptor internalization, and degradation. This ubiqui-
tination did not occur with a catalytically inactive Nedd4 or 
with mutant Grb10 unable to bind Nedd4 [120]. This work 
identified Nedd4 as an ubiquitin e3 ligase and Grb10 as the 
key adaptor protein to recruit Nedd4 to the IGF-1R. Fur-
ther work from the Morrione laboratory described Nedd4 
ubiquitination of the IGF-1R as predominantly of multi-
monoubiquitination type [131]. In addition, the internali-
zation mediated by Nedd4 was both clathrin- and caveo-
lin-dependent as demonstrated by co-localization studies 
[131].
Following original research demonstrating a feedback 
mechanism of wild-type p53 negatively regulating IGF-1R 
at the transcriptional level [132], it was revealed that over-
expressed mutant or wild-type p53 mitigate ligand-induced 
IGF-1R downregulation [29]. Analysis of IGF-1R mRNA 
levels discard an exclusively transcriptional mechanism, 
indicating a posttranslational p53-IGF-1R control mecha-
nism [29]. Further work demonstrated that an inhibition 
of p53 caused ubiquitination and degradation of the IGF-
1R, suggesting that p53 and IGF-1R might compete for 
the same ubiquitin ligase [116]. This possibility was vali-
dated in experiments in which inhibition of Mdm2 (the 
well-known p53 ubiquitin ligase) resulted in accumulation 
of IGF-1R [116]. This work confirmed the direct IGF-
1R/Mdm2 interaction, identified Mdm2 as an ubiquitin 
ligase for the IGF-1R, promoting proteasome-inhibitor-
sensitive IGF-1R degradation, and highlighted a positive 
posttranslational control mechanism between p53 and 
IGF-1R [116]. Subsequent research revealed the mecha-
nism of Mdm2 binding to the IGF-1R by identifying that 
β-arrestins, otherwise known as master regulators of GPCR 
biology, serve as adaptors to bring the e3 ligase Mdm2 to 
the IGF-1R [133]. Both Mdm2 and β-arrestin co-immu-
noprecipitated with the IGF-1R and in an in vitro reaction 
β-arrestins enhanced Mdm2-mediated IGF-1R ubiquitina-
tion [133]. In a cell system, overexpression or depletion 
of β-arrestin 1 enhanced and decreased IGF-1R ubiquit-
ination and degradation, respectively. Thus, β-arrestin 1 
was proved to act as an essential component in the ubiq-
uitination and downregulation of the IGF-1R [133]. Most 
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recently, β-arrestin 1 was recognized not only as an aid to 
IGF-1R internalization and signal cessation but to initi-
ate its own second wave of signaling through the MAPK/
eRK pathway [134], with IGF-1R stimulation also lead-
ing to ubiquitination of β arrestin 1 [134]. Intriguingly, this 
β-arrestin 1-mediated eRK activation occurs even when the 
classical IGF-1R kinase signaling is impaired (see below) 
[134]. Taken together, these studies demonstrated that 
β-arrestin 1 serves as an adaptor to bring the e3 ubiquitin-
ligase Mdm2 to the IGF-1R, with a dual outcome on the 
IGF-1R: ubiquitination and receptor downregulation as 
well as IGF-1R/β-arrestin 1-mediated activation of MAPK 
signaling.
The identification of c-Cbl as an ubiquitin-ligase for 
IGF-1R [117] was based on the observation that suppres-
sion of Mdm2 did not completely abolish ligand-induced 
IGF-1R ubiquitination, suggesting that there are other 
ligases contributing to this process. Previously recog-
nized as an e3 ligase of other RTKs, including eGFR and 
PDGFR [135], c-Cbl was demonstrated to associate with 
and to ubiquitinate the IGF-1R [117], especially at higher 
doses of IGF-1, indicating complementary roles for the dif-
ferent e3 ligases [117]. In vitro experiments using ubiq-
uitin with mutated lysine residues suggested that Mdm2 
polyubiquitinates IGF-1R with K63 type chains, whereas 
c-Cbl polyubiquitinates IGF-1R with K48 type chains. 
Co-localization between caveolin and an early endosome 
marker showed that higher doses of IGF-1 increased cave-
olin-mediated endocytosis, whereas low doses did not. In 
agreement with IGF-1 concentration determining ligase 
and endocytotic processes, overexpression of Mdm2 could 
reduce caveolin-mediated endocytosis.
The e3 ligases Mdm2 and Nedd4 have been demon-
strated to bind to the IGF-1R through the adaptor proteins 
β-arrestin 1 [133] and Grb10 [131], respectively, suggest-
ing that adaptor proteins determine substrate specificity. 
For Nedd4, there is evidence of the ligase determining 
appropriate localization of the receptor [136], and that it 
directs towards a proteasome-independent pathway of deg-
radation [137]. The ligases c-Cbl and Mdm2 appear to have 
complementary roles, with c-Cbl recruited following high 
dose IGF-1 and initiating caveolin-dependent endocytosis 
and Mdm2 recruited at low dose IGF-1 and initiating clath-
rin-dependent endocytosis [117]. It is clear, however, that 
different ligases associated with the IGF-1R as well as their 
adaptor proteins have redundant as well as complementary 
roles: they keep the balance between recycling, relocaliza-
tion, and proteasome/lysosomal degradation of the receptor 
[117, 120, 121, 131, 133, 134]. The complexity is further 
increased by the fact that receptor signaling relies on its 
localization: signaling still occurs from endosomes and pre-
vention of endocytosis is even inhibitory to signaling [84, 
124, 134, 138].
Through IGF-1R mutation analysis, the interplay 
between phosphorylation and ubiquitination has been 
demonstrated [121]. According to this study, a completely 
kinase-dead IGF-1R (with mutation of the ATP pocket) 
cannot be ubiquitinated after ligand stimulation, while a 
kinase impaired IGF-1R (Y1136A) is ubiquitinated, acti-
vates eRK signaling, but fails to phosphorylate Akt. Dele-
tion of the C-terminal tail (Δ1245) had no effect on IGF-1R 
phosphorylation but completely abolished its ubiquitination 
[121], confirming the previous findings that IGF-1R ubiq-
uitination is essentially dependent on its β-arrestin binding 
domain [133, 134].
Although initially described as a modification initiated 
by the natural ligand binding to the receptor, recent studies 
suggest that IGF-1R ubiquitination is a more complex pro-
cess that can also be activated kinase-dependent (activation-
loop phosphorylation) by IGF-2 [139], insulin [139], LL-37 
[140], or kinase-independent by anti-IGF-1R antibodies 
[140–142]. In addition, IGF-1R ubiquitination can be acti-
vated in a ligand and kinase-independent manner, from 
inside the cell, by adaptor proteins recruited to the intracel-
lular domain of the IGF-1R [124, 143, 144]. The mecha-
nism of IGF-1R ubiquitination is different depending on 
the ligand, adaptor protein, or ubiquitin-ligase employed; 
however, the common theme is that a specific receptor con-
formation may trigger ubiquitination with divergent effects 
on receptor signaling, trafficking, and biological outcomes. 
It should be noted here that such conformation-activating 
ubiquitination is not essentially dependent on ligand–recep-
tor interaction or activation-loop phosphorylation.
IGF-1R dephosphorylation
Direct IGF-1R dephosphorylation has been little investi-
gated. Rocchi et al. [145] described the association of acti-
vated IGF-1R with the phosphatase SHP2, with binding 
between phospho-tyrosines on IGF-1R and SH2 domains 
in SHP2 being critical. Subsequently, it was demonstrated 
that SHPS2 is critical for recruitment of SHP2 to the 
plasma membrane for this purpose [146]. Cross-talk with 
the αvβ3 integrin, through SHP2, was later described, with 
blockage of this integrin reducing IGF-1-induced IGF-1R 
phosphorylation [146, 147]. The phosphatase PTP1B also 
negatively regulates the IGF-1R [148], associating with it 
in a ligand-dependent manner [149].
Nuclear IGF-1R
Recently, there has been greater appreciation of plasma 
membrane receptor relocalization to the nucleus. Nuclear 
localization has been demonstrated for the IGF-1R and 
shown to be mediated by sumoylation, the addition of a 
small protein similar to ubiquitin [150, 151]. The direction 
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to the nuclear compartment and the role of nuclear IGF-1R 
is currently little investigated, but studies suggesting that 
IGF-1R nuclear localization can alter transcription [152], 
and that nuclear localization of IGF-1R predicts better out-
come in patients treated with IGF-1R antibody [153], sug-
gest that further research would have therapeutic relevance. 
One study has demonstrated that transfer to the nucleus is 
mediated at least in part by clathrin, and confirmed that 
both the α- and β-chains of IGF-1R translocate to the 
nucleus [154], suggesting a more complex function to IGF-
1R internalization than solely degradation versus recycling. 
The emerging role of nuclear IGF-1R has recently been 
thoroughly reviewed by Sarfstein and werner [155].
Something borrowed: IGF‑1R transactivation by other 
plasma‑membrane receptors
It is generally accepted that several posttranslational modi-
fications control the IGF-1R levels at the cell surface, with 
direct impact on receptor signaling. Are these modifica-
tions, in combination with the “two-states” model, suf-
ficient to explain the differential signaling efficacy of the 
IGF-1R? Described by terms such as “cross-talk” or “trans-
activation”, it is increasingly recognised that IGF-1R sign-
aling and efficacy is modified by interactions with other 
plasma-membrane molecules. This group include other 
RTKs, integrins, and GPCRs. Among the RTKs, prob-
ably the best studied is the IGF-1R interaction with the IR, 
resulting in formation of hybrid receptors [187, 188] which 
are able to respond to insulin, IGF-1, and IGF-2 but with 
different affinities. The mechanism of hybrid receptor acti-
vation, signaling, as well as their biological effects, have 
been extensively investigated [37, 139, 156–158]; however, 
it should be highlighted here that simple interaction of the 
IGF-1R with IR modified IGF-1R signaling and trafficking 
to various ligands [139] and anti-IGF-1R antibodies [156]. 
The IR is not the only RTK associated with the IGF-1R; 
for example, a direct interaction between the IGF-1R and 
eGFR was identified in cancer cells, with eGFR depletion 
affecting IGF-1R ubiquitination, degradation, and signaling 
[159]. In a similar manner, another group of plasma-mem-
brane molecules were demonstrated to modify the IGF-1R 
response to IGF-1. Integrins, as transmembrane receptors, 
transfer information from the extracellular matrix (eCM) 
to signaling pathways inside cells (outside–in signaling) 
or from within the cell (inside–out signaling) [160]. They 
form part of cell surface signaling complexes known as 
focal adhesions which link the cytoskeleton to the eCM 
and are intimately linked with cell adhesion and migra-
tion [160]. There has been increasing recognition of the 
bi-directional cross-talk between integrins and the IGF-1R 
signaling pathway [161]: integrin activation modulating the 
IGF-1R signaling and vice versa. Studies identifying the 
overlap between IGF-1R and integrin signaling pathways 
from the Clemmons group demonstrated IGF-1R-depend-
ent “transactivation” of αvβ3 integrin [162]. The mecha-
nism was described as due to the recruitment and phos-
phorylation/dephosphorylation of adaptor proteins. IGF-1 
stimulation causes phosphorylation of the transmembrane 
adaptor protein SHPS1 and subsequent SHP2 recruitment 
[146]. Along with SHP2, IGF-1R through IRS1 recruits the 
focal contact adaptor protein paxillin and FAK, which are 
involved in the turnover of focal contacts. IGF-1 stimula-
tion leads to SHP2 dephosphorylation of paxillin and FAK, 
as part of an integrin deactivation mechanism crucial for 
migration [163]. In further evidence, the DOK1 protein, 
itself an IRS protein, brings SHP2 to the αvβ5 integrin 
[164]. IGF-1 is well known to initiate cell migration, IGF-1 
triggers integrin activation and binding to eCM [165], and 
evidence showed that αvβ3 and αvβ5 are involved in the 
migratory/invasive IGF-1 response [165, 166].
However, there is also increasing recognition that the 
activation state of integrins alters IGF-1R signaling. The 
SHP2 protein is not only recruited to integrins and dephos-
phorylates paxillin and FAK but regulates IGF-1R dephos-
phorylation, curtailing the IGF-1R signaling response 
[146], identifying it as a common molecule between the 
integrin and IGF-1R signaling pathways. The Clemmons 
group also describe integrin modulation of the SHPS1-
IGF-1R association, with activation and tyrosine phospho-
rylation of αvβ3 integrin determining the recruitment to the 
IGF-1R of SHPS1 and subsequently SHP2, and involving 
IAP [167, 168]. Overall, ligand occupancy of at least some 
integrins is required for a sustained IGF-1 response [169], 
and transmembrane integrin complexes including SHPS1 
and IAP modulate IGF-1R signaling through determining 
SHP2 recruitment (reviewed in [170]), with subsequent 
effects on cell behavior [171].
The O’Connor group described a further common node 
between integrins and IGF-1R. The RACK1 scaffolding-
protein, known to interact with β1 integrin, was identified 
as also binding IGF-1R affecting Shc/Grb2 downstream 
signaling [87, 172]. Further, the O’Conner group demon-
strated that RACK1 associated mutually exclusively with 
phosphatase PP2A or β1 integrin, controlled by IGF-1 
stimulation [173]. However, this complex differed between 
transformed and non-transformed cells, with only trans-
formed cells showing direct RACK1–IGF-1R interaction 
[174].
Recent work by the Takada group posited an extracel-
lular determinant of cross-talk between the two pathways, 
in agreement with the co-localization of IGF-1R and inte-
grins together at focal adhesion complexes. They demon-
strated direct binding of IGF-1 ligand to αvβ3 integrin and 
α6β4 integrin and direct effects on IGF-1R signaling [175], 
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including sustaining of cells during anchorage independ-
ence [176] [177]. In their further work, an IGF-1 mutant 
unable to bind integrins but able to bind IGF-1R had a 
dominant negative effect on IGF-1R-mediated tumorigen-
esis in vivo [178], suggesting further functional effects of 
such ternary complexes.
Together, these data show that integrin activation is able 
to modify the phosphorylation and signaling from the IGF-
1R and subsequently the biological outcomes. As men-
tioned before, in addition to RTKs and integrins, members 
of the GPCR family, can modify the IGF-1R responsive-
ness to different ligands.
Something borrowed: IGF‑1R utilize components 
of GPCR signaling
It is generally accepted that RTKs share signaling pathways 
with the larger class of the GPCRs [3, 179]. Over the last 
decades, at least two mechanisms of receptor cross-talk 
between RTKs and GPCRs have been described: recep-
tor transactivation and RTK signaling through GPCR 
components.
RTK transactivation is typically explained as the GPCR-
dependent increase in phosphorylation, kinase activity, and 
signaling of the RTK. One example is represented by the 
lysophosphatidic acid (LPA) transactivation of the eGFR 
[180]: LPA, a classical GPCR agonist, triggers eGFR auto-
phosphorylation and MAPK signaling activation, effects 
that are sensitive to eGFR-kinase inhibitors or expression 
of eGFR kinase-defective mutants [180]. Although not 
completely understood, the mechanism of LPA-induced 
transactivation of eGF receptors is likely to involve the 
release of an eGFR ligand by a GPCR-activated metal-
loproteinase. Several other RTKs, including the ones for 
PDGF, veGF, and NGF, were reported to be transactivated 
by GPCR agonists such as LPA, angiotensin, endothelin, 
and bradykinin (for review, see [179]). It is noteworthy that 
RTK transactivation by GPCRs required tyrosine phospho-
rylation and kinase activity of the growth factor receptor 
and is sensitive to inhibitors of receptor kinases [179, 181]. 
The IGF-1R is not an exception from this rule: transacti-
vation and phosphorylation of the IGF-1R with subsequent 
MAPK activation was reported following thrombin stimu-
lation of aortic smooth muscle cells [182]. Several other 
GPCR-agonists were described as IGF-1R transactivators, 
including neurotensin [183] and vasopressin [184].
The second mechanism used to explain RTK/GPCR 
cross-talk is the employment of the GPCR signaling com-
ponents, G-proteins and β-arrestins, by the RTKs for their 
signaling activation. Characteristic of this type of signal-
ing is the response to G-protein signaling inhibitors (e.g., 
pertussis toxin which uncouples Gαi from an activated 
receptor), G-protein sequestration [185], or β-arrestin 
downregulation [144, 186]. Most if not all RTKs, includ-
ing PDGFR, eGFR, and veGFR, utilize G-proteins as 
signaling mediators (for in depth reviews, see [3, 179, 181, 
187]). In this context, it is worth mentioning that the mem-
bers of the IR family were the first described to engage 
the G-proteins signaling: the IR signaling was demon-
strated to be sensitive to pertussis toxin treatment [186], 
with subsequent decrease of the insulin-induced inhibition 
of adenylyl cyclase in isolated hepatocytes [188]. Several 
other studies have demonstrated the Gαi involvement in 
IR signaling and their effects on insulin signaling biologi-
cal outcomes [186, 189]. Given the high structural simi-
larities between IR and IGF-1R, it is not surprising that 
some G-proteins have also been identified to physically 
associate and mediate IGF-1R signaling. Almost 20 years 
ago, a study from Robert Lefkowitz’s laboratory reported 
that IGF-1R-dependent activation of the MAPK signal-
ing pathway was inhibited by the Gαi-inhibitor pertussis 
toxin or by sequestration of G-protein βγ subunits by a 
peptide derived from GRK2 [185]. This study clearly dem-
onstrated that IGF-1R signaling depends on heterotrimeric 
G-proteins containing the Gαi and Gβγ subunits. Consist-
ent with these observations, subsequent studies demon-
strated that, in rat neuronal cells or mouse fibroblasts, Gαi 
and Gβ subunits were associated with IGF-1R while Gαs 
was not associated with the IGF-1R in any cell type. More 
importantly, this study demonstrated the IGF-1 induced 
release of the Gβ subunits from the IGF-1R with no effect 
on IGF-1R/Gαi association, indicating a discrete pool of 
Gβγ subunits available for IGF-1R downstream signal-
ing [190]. The IGF-1R/Gαi association was also reported 
in a separate study investigating the roles of heterotrim-
eric G-protein signaling components in insulin and IGF-1 
signaling. In 3T3L1 adipocytes, in basal state, Gαi and Gβ 
were associated with the IGF-1R, while IGF-1 stimulation 
increased the IGF-1R/Gαi association, releasing the Gβ 
subunits [144].
while RTK transactivation by GPCRs has long been 
recognized and is today considered a “classical” signal-
ing pathway, the complexity of the RTK/GPCR cross-talk 
was further demonstrated by recent findings of bidirec-
tional cross-communication between RTKs and GPCRs 
(for in depth reviews, see [181, 187]). In these processes, 
the GPCR signaling is activated by RTKs by the same 
two mechanisms described above: production of a GPCR 
ligand stimulated by RTK activation or a ligand-independ-
ent cross-activation of the signaling network [181, 187]. 
In the case of the IGF-1R, such GPCR-transactivation has 
been demonstrated to be essential for migratory and pro-
survival functions controlled by IGF-1 [181, 187]. Taken 
together, these studies indicate a common signaling plat-
form between IGF-1R and GPCRs to differentiate between 
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the responses upon combined growth factor/GPCR agonist 
stimulation from single stimulation by either ligand.
The corollary of these studies is that IGF-1R (and IR) 
can activate signaling as a GPCR, using different G-protein 
partners for downstream signaling. The Gαi subunit is con-
stitutively associated with the IGF-1R while IGF-1 treat-
ment leads to GTP loading of Gαi2 [144] and Gβγ disso-
ciation. Yet, these findings raise another critical question: if 
IGF-1R and IR can activate G-protein signaling, what is the 
system desensitizing this pathway? In the case of GPCRs, 
the signaling is terminated by β-arrestin recruitment to the 
activated receptor. early studies demonstrated the involve-
ment of β-arrestin in IGF-1R signaling and trafficking: a 
dominant negative mutant of β-arrestin 1 was demonstrated 
to impair IGF-1R internalization, whereas overexpression 
of wild-type β-arrestin 1 or β-arrestin 2 increases IGF-
1R internalization [191]. Moreover, G-protein signaling 
activated by IGF-1R was demonstrated to be sensitive to 
β-arrestin inhibition [144].
The discovery of the dual regulatory role of β-arrestin 
1 in the case of IGF-1R, downregulation [133], and sign-
aling activation [134], pointed towards a remarkable par-
allel with the role of β-arrestins in the case of the larger 
GPCR family. while internalizing the GPCR and ending 
G-protein signaling, β-arrestins activate the MAPK path-
way [192–194].
Recognized as a universal mechanism of GPCR regu-
lation, β-arrestin 1 binds to the receptor and desensitizes 
G-protein signaling only after phosphorylation of specific 
serine residues by the G-protein–coupled receptor kinases 
(GRKs) [193, 195, 196]. Therefore, a legitimate ques-
tion was whether the same mechanism is in place for the 
IGF-1R.
Investigating this scenario, we found that activated IGF-
1R allows recruitment of the GRK proteins, specifically 
with contrasting effects between GRK2 and GRK6 [124]. 
Subsequent GRK2- or GRK6-dependent phosphorylation 
of IGF-1R C-terminal serine residues 1248 or 1291, respec-
tively, allows β-arrestin 1 recruitment, with the residue that 
is phosphorylated controlling the duration and strength of 
the β-arrestin/IGF-1R association.
Identification of GRK-dependent phosphorylation of 
IGF-1R serine residues as the underlying mechanism for 
β-arrestin/IGF-1R interaction not only revealed another 
connection to the complex cross-talk between the IGF-1R 
and GPCR but in fact provided the missing link to func-
tionally identify IGF-1R as a GPCR. This paradigm shift is 
founded on the accepted universal model of GPCR activa-
tion and desensitization delineated by six distinct processes 
[195, 197], all of which have been identified to occur for 
the IGF-1R (Fig. 3): (1) ligand binding to the IGF-1R, in 
addition to the classical kinase signaling cascade triggers 
signaling through heterotrimeric G-proteins [144, 185], 
(2) subsequent GRK2- or GRK6-dependent phosphoryla-
tion of IGF-1R C-terminal serine residues 1248 or 1291, 
allowing β-arrestin binding to these specific phosphoryl-
ated serine residues [124], with (3) β-arrestin recruitment 
[124, 133, 134], (4) subsequent kinase/G-protein signal-
ing desensitization, (5) activation of a β-arrestin-dependent 
second signaling wave through MAPK [124, 134], and 
(6) receptor endocytosis with the GRK isoform determin-
ing receptor degradation [124, 133] or recycling [124]. In 
this model, one uncertainty is whether, for the IGF-1R, 
GRK-mediated β-arrestin binding initiates a desensiti-
zation process (Fig. 3, Iv) and whether the desensitiza-
tion process affects both G-protein and kinase signaling. 
while for GPCRs the key role of GRKs in desensitization 
is well recognized, for RTKs few studies have investigated 
the contribution of GRKs [3]. In all published studies, 
GRK2 is reported to desensitize or modulate RTK signal-
ing. For instance, GRK2 is recruited and co-localizes with 
the ligand-activated eGFR or PDGFR, leading to recep-
tor serine phosphorylation and increased eRK activation 
in the case of eGFR [198], or inhibiting the kinase activ-
ity in the case of PDGFR [199]. The insulin receptor (IR), 
closely related to the IGF-1R, is a special case: GRK2 was 
shown to have inhibitory effects on IR-mediated signaling 
and glucose uptake, though the observed effects were dem-
onstrated to be mediated in a kinase-independent manner 
through GRK2 sequestration of Gαq/11 [200].
For GPCRs, the desensitization requires the membrane 
localization of GRKs. In a palmitoylated state, GRK6 has 
been found to be exclusively associated with the mem-
brane; however, it is not yet clear whether this revers-
ible posttranslational modification is induced by activated 
receptor [3]. On the other hand, a clear regulatory negative 
feedback, induced by activated receptor, was demonstrated 
for GRK2: Gβγ subunits, generated by the agonist-occu-
pied receptor, interact with GRK2 and serve to target this 
enzyme into proximity with its membrane receptor sub-
strate [201]. Consequently, β-arrestin recruitment to GRK-
phosphorylated receptors physically prevents the coupling 
of receptor to its cognate G-protein. Thus, a true compari-
son of IGF-1R desensitization with GPCR desensitization 
would make sense only if IGF-1R utilizes heterotrim-
eric G-proteins for its signaling. Our results showing that 
GRK2 is involved in limiting the eRK response to IGF-1 
fully support the GRK2 desensitization function in the case 
of IGF-1R. For GRK6, our interpretation is that prolonged 
eRK activation is due to the second wave of signaling acti-
vated by the stable β-arrestin recruitment to the IGF-1R 
(Fig. 3, v), masking the desensitization of the first signal-
ing wave. Taken together, the proposed model represents 
IGF-1R as not only “borrowing” components of GPCR 
signaling but to operate as a functional hybrid RTK/GPCR 
(Fig. 3).
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The emerging paradigm for IGF‑1R signaling
A major limitation of the two-state model for IGF-1R sign-
aling is the explanation of the two main components of 
the IGF-1R activity: the signaling activation and receptor 
downregulation as separate events. In this paradigm, all 
receptors are equal and the receptor activity is exclusively 
and directly related to kinase activation by ligand–receptor 
interaction. Signaling, and downregulation triggered simul-
taneously by the ligand-activated receptor. Both involve 
phosphorylation, ubiquitination, and probably other post-
translational modifications. The logical conclusion is that 
receptor signaling and degradation never dissociate from 
each other or from ligand-induced receptor (kinase) activa-
tion. Moreover, in the same cellular context, the MAPK/
eRK and PI3K/Akt pathways are described as being 
activated in a balanced manner following IGF-1R stimu-
lation. Yet, there is experimental data that do not support 
this model, including some major contradictions (Table 2) 
such as kinase-independent signaling activation [124, 134, 
202] or unbalanced signaling in the same cellular back-
ground [34, 124, 134], signaling-degradation dissociation, 
or receptor downregulation in the absence of the ligand or 
activation-loop phosphorylation [37, 124, 203]. Beyond 
this, there is the major paradox of the IGF-1R inhibitors 
(antibodies and small molecules inhibitors, see below), 
which are able to activate IGF-1R downregulation and 
signaling despite clear inhibitory effects on receptor tyros-
ine phosphorylation. 
The appreciation of the dual functions of β-arrestin, as a 
mediator of IGF-1R signaling [124, 134, 191, 204] as well 
as mediator of receptor downregulation [124, 133], provide 
Fig. 3  IGF-1R as a RTK/GPCR functional hybrid. Signaling: ago-
nist-stimulation of the IGF-1R triggers the classical RTK signaling 
leading to downstream kinase-cascade signaling activation. In addi-
tion, agonist-stimulation of IGF-1R leads to non-canonical GPCR 
signaling through heterotrimeric G-proteins (G α, β, γ) (I), following 
which the receptors are rapidly phosphorylated by G-protein-coupled 
receptor kinases (GRKs) at serine residues within the C-terminus (II). 
Desensitization: Serine-phosphorylated receptors present high affinity 
binding sites to recruit the multifunctional adaptor protein β-arrestin 
1 (β1) (III). Steric binding by β-arrestin to the IGF-1R C-terminal 
prevents further G-protein coupling, leading to the desensitization of 
G-protein-dependent signaling (IV). β-arrestin signaling: β-arrestin 
acquires an active conformation upon binding the IGF-1R and scaf-
folds components of the MAPK pathways leading to the activation 
of a second wave of IGF-1R kinase independent signaling through 
β-arrestin 1 (V). The dynamics of this signaling activation is deter-
mined by the strength of the β-arrestin 1/IGF-1R interaction, depend-
ent on GRK-isoform (VI) Such β-arrestin-dependent MAPK activity 
has been shown to regulate multiple IGF-1R biological effects includ-
ing proliferation, apoptosis, cell migration, and cancer metastasis. 
endocytosis: agonist-stimulation promotes rapid endocytosis of the 
IGF-1R. This internalization is enabled by β-arrestin binding, con-
necting the receptor to the endocytic machinery efficiently. The inter-
action between β-arrestin and the e3 ubiquitin ligase Mdm2 promotes 
IGF-1R and β-arrestin ubiquitination that facilitates IGF-1R endo-
cytosis, followed by post-endocytic sorting of internalized IGF-1R. 
The strength of the β-arrestin 1/IGF-1R interaction GRKs-isoform-
dependent determines the fate of internalized receptor: recycling 
(transient β-arrestin 1 binding) or degradation (sustained β-arrestin 1 
binding) (VI)
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the basis for the emerging paradigm of IGF-1R signaling. 
In this model, IGF-1R can initiate classical kinase sign-
aling, β-arrestin signaling, and heterotrimeric G-protein 
signaling as well as β-arrestin-mediated receptor desensi-
tization (Fig. 4). However, the receptor conformation acti-
vating the kinase signaling can be distinct from that which 
interacts with β-arrestins, as demonstrated by the IGF-1R 
mutants constitutively binding β-arrestin, that are degraded 
even in the absence of the ligand [124] (Fig. 4). This sce-
nario can explain the dissociation between kinase activa-
tion and receptor degradation as well as kinase-independent 
signaling. The same model would also accommodate the 
unbalanced IGF-1R signaling, activated in a “biased man-
ner” via β-arrestin by IGF-1R inhibitors as well as by natu-
ral “biased” agonists [22, 143]. In this emerging model, not 
all receptors are equal and their activity can be modulated 
from inside the cell by particular posttranslational modifi-
cations (e.g., serine phosphorylation, ubiquitination, etc.) 
or by interacting proteins (e.g., β-arrestins, integrins, other 
RTKs).
Implications for treatment
Owing to its essential role in maintaining the malignant 
phenotype, IGF-1R-targeted therapy was considered a 
very promising strategy for cancer treatment [205–214]. 
Although several approaches targeting the IGF-1R were 
employed to prove the concept, the common aim for all 
these strategies is the inhibition of the classical kinase 
signaling cascade (for reviews, see [26, 27, 91, 215]). This 
can be accomplished either by preventing ligand–receptor 
interaction (e.g., using blocking antibodies) or silencing the 
effects of this interaction (e.g., tyrosine kinase inhibitors, 
TKIs).
Strategies aimed at blocking the ligand–receptor 
interaction
Receptor downregulation was among the first approaches 
used to prevent ligand–receptor interaction and to validate 
IGF-1R as a therapeutic target [216]. This was achieved 
by antisense oligonucleotides, plasmids expressing IGF-
1R antisense cDNA or triple helix-forming oligodeoxy-
nucleotides [23]. The same outcome was obtained with 
drugs interfering with IGF-1R glycosylation, folding and 
expression at the cell surface (tunicamycin or lovasta-
tin) [17–19, 217] or by directly increasing receptor deg-
radation [114, 218]. The majority of these systems were 
unsuitable for transfer to the clinic, either because they 
were unable to be delivered or because they were too 
unspecific, so the next work in this area focused on clini-
cally suitable methods for blocking the ligand–receptor 
interaction.
Table 2  The new paradigm for IGF-1R signaling
The contradictory evidence against the two-state model is described and how the new paradigm can explain these data
Classical paradigm and its contradictions emerging paradigm
Receptor activity is exclusively and directly related to kinase activation 
by ligand–receptor interaction
Contradiction: kinase-independent signaling activation: IGF-1R can 
trigger MAPK signaling in the absence of the ligand or without 
kinase domain activation [124, 134, 202]
In addition to classical RTK signaling, IGF-1R operates as a functional 
GPCR
In this model, IGF-1R can initiate kinase-independent signaling such as 
β-arrestin signaling and heterotrimeric G-protein signaling
Signaling and receptor downregulation are triggered simultaneously by 
the ligand-activated receptor in a balanced manner
Contradictions: signaling–downregulation dissociation-specific 
point-mutations outside the kinase domain can activate signaling or 
receptor downregulation in the absence of the ligand or activation-
loop phosphorylation [124]
IGF-1R downregulation induced by ligands other than IGF-1 (e.g., 
antibodies)
Unbalanced signaling downregulation induced by IGF-1R transactiva-
tion (e.g., hybrid receptors, integrins, other GPCR or RTKs)
The receptor conformation activating the kinase signaling can be 
distinct from that which interacts with β-arrestins facilitating receptor 
ubiquitination and endocytosis in the absence of kinase activity
This model can explain the dissociation between kinase activation and 
receptor degradation as well as ligand- or kinase-independent signal-
ing or receptor downregulation triggered by kinase inhibitors (e.g., 
targeting antibodies) or IGF-1R partners
equal receptors with balanced activation of the downstream signaling 
pathways (MAPK/eRK and PI3K/Akt pathways)
Contradictions: unbalanced signaling: in the same cellular back-
ground, IGF-1R can preferentially activate either the MAPK or 
PI3K/AKT pathways [34, 124, 134]
The paradox of the IGF-1R inhibitors (antibodies and small molecules 
inhibitors) which are able to activate IGF-1R signaling despite clear 
inhibitory effects on receptor tyrosine phosphorylation
The receptor conformation activating the kinase signaling can be dis-
tinct from that which interacts with β-arrestins or with other partners
In this model, not all receptors are equal and their activity can be 
modulated from inside the cell by particular posttranslational modi-
fications (e.g., serine phosphorylation, ubiquitination, etc.) or by 
interacting proteins (e.g., β-arrestins, IR, integrins, etc.)
The same model would also accommodate the unbalanced IGF-1R 
signaling, activated in a “biased manner” via β-arrestin by IGF-1R 
inhibitors as well as by natural “biased” agonists
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Competition with the ligand–receptor interaction
In this category are included strategies that involve upreg-
ulation of the IGFBPs, the natural IGF inhibitors [219], 
IGFs peptide analogues [219, 220], or ligand or receptor 
neutralizing antibodies [206, 221]. There are seven differ-
ent IGFBPs, most of them have been shown to inhibit the 
actions of IGFs. In vitro and in vivo experiments indicate 
that increasing IGFBPs could be an alternative to IGF-
1R targeting, particularly due to the lack of interference 
with insulin signaling [222]. There is also evidence that 
free IGFBPs have anti-tumor activity independent of their 
IGF-binding capacity [223]. Anti-ligand antibodies, devel-
oped to mimic IGFBP action, have a high affinity against 
both IGF-1 and IGF-2, and do not cross-react with insulin 
[224–226]. Several antibodies targeting IGF-1 or IGF-2 
have been reported, with one reaching clinical trial [225]. 
They prevent signaling through the IGF-1R and the hybrid 
receptors, but, importantly, they do not affect insulin-stim-
ulated phosphorylation of the insulin receptor (IR) and its 
downstream signaling. while most of the ligand-targeting 
antibodies bind to both IGFs, a few have higher affinity 
for IGF-2 [224, 226, 227]. Notably, antibody sequestration 
of ligand can lead to high levels of free IGFBPs, a conse-
quence that might improve their intended effect [93].
Antibodies against the extracellular ligand binding 
domain of the IGF-1R were designed to block ligand–
receptor interaction [27, 93]. This strategy was considered 
to be very promising, and therefore most of the large phar-
maceutical companies developed anti-IGF-1R antibodies 
and those demonstrating significant activity in preclinical 
settings were taken forward for clinical evaluation [27, 93]. 
However, in clinical settings, treatment with anti-IGF-1R 
antibodies induced clinical responses only in some cases 
A B
Fig. 4  New and old paradigms of IGF-1R signaling: balanced and 
biased signaling at the IGF-1R. a Classical model: IGF-1R activation 
is triggered exclusively by ligand-binding and signaling is mediated 
by kinase cascade through phosphorylation. Ligand-activated IGF-
1R leads to balanced phosphorylation-dependent Akt/eRK signal-
ing and balanced signaling/downregulation. b New paradigm. In 
the current model for IGF-1R activation, in addition to the classical 
RTK-cascade, binding of a ligand results in activation of signaling 
by G-proteins and β-arrestins, as well as desensitization and inter-
nalization by β-arrestins. In a system with balanced signaling, ligand-
binding results in balanced activation of kinase signaling, signaling 
by G-proteins and β-arrestins, as well as desensitization and internali-
zation by β-arrestin. In a system with biased signaling, two alterna-
tive outcomes of receptor activation are depicted: kinase/G-protein-
biased with enhanced IGF-1R phosphorylation and β-arrestin-biased 
with enhanced IGF-1R ubiquitination. Biased signaling is a feature 
of the ligand–receptor complex so either the receptor or the ligand 
could be biased. An IGF-1R biased ligand elicits one response over 
another compared with the classical ligand, (e.g., anti-IGF-1R favors 
β-arrestin signaling). A biased IGF-1R is only efficient at activating 
a restricted subset of downstream signaling pathways (e.g., mutant 
receptors)
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of ewing’s sarcoma (eS) [228–230] and selected cases of 
lung carcinoma [93, 231, 232]. Although not chosen by 
design, all anti-IGF-1R antibodies used in clinical trials, 
besides inhibiting IGF-1-induced receptor phosphorylation, 
also trigger receptor downregulation ([140] and below).
Strategies aiming to inhibit IGF-1R signaling
The proof of mechanism for this approach is represented 
by IGF-1R kinase-dominant negative mutants, success-
fully tested in preclinical settings by several laboratories 
[211, 233]. Cells transfected to express IGF-1R cDNA 
with kinase-inactivating [234] or kinase-limiting muta-
tions [235, 236], lose their malignant phenotype as well as 
their invasive and metastatic potential [237]. The promising 
strategy of inhibiting IGF-1R kinase activity is complicated 
by IR cross-reactivity issues, as the kinase domain of the 
IGF-1R shares 85 % homology with that of the IR, with the 
ATP binding cleft 100 % conserved [40]. Nevertheless, sev-
eral small inhibitors have been developed (for review [238, 
239]) and despite some of them having shown signs of 
cross-reactivity with the IR, they are still considered for use 
in clinical settings. Additionally, there is recent evidence 
and debate in the literature as to whether co-inhibition of 
the IR is beneficial for anti-IGF-1R therapy [240, 241]. 
while all small molecules targeting IGF-1R prevent kinase 
activation, they can be further divided in two subgroups, 
based on their mechanism of action: inhibitors of the ATP 
binding cleft or inhibitors of the kinase–substrate interac-
tion, including inhibitors of the A-loop. Among the first 
category, NvP-Aew541 and NvP-ADw74 inhibit IGF-1R 
kinase activity and appear to be equipotent for both IGF-1R 
and IR inhibition in vitro, yet they show selectivity for the 
IGF-1R in intact cells. The two drugs were tested in various 
models such as fibrosarcoma, myeloma, and eS [242, 243]. 
Another small molecule, OSI-906 is a dual IGF-1R/IR 
kinase inhibitor with a strong anti-tumoral efficiency in 
an IGF-IR-driven xenograft model [244]. There have been 
several such inhibitors tested in clinical trials [27], and 
what they have in common is that inhibition of the ATP-
binding also prevents IGF-1R downregulation. This is not 
surprising as in vitro experiments clearly demonstrated that 
IGF-1R ATP-defective mutants are not ubiquitinated [121].
Among the second category of the IGF-1R kinase 
inhibitors (TKIs), the cyclolignan picropodophyllin (PPP) 
demonstrates a special feature for this class. PPP was origi-
nally described to inhibit the IGF-1R without altering the 
IR, reducing Akt phosphorylation [20] and inducing tumor 
regression in xenografted mice. Rather than competing 
with ATP, PPP differs from other IGF-1R TKIs by inter-
fering with phosphorylation of the kinase domain A-loop. 
PPP specifically blocked phosphorylation of the tyrosine 
(Y) 1136 residue, while sparing the two others (Y1131 and 
Y1135), suggesting that it might act as a substrate inhibi-
tor [245]. Since its discovery [20], PPP has been proven to 
inhibit IGF-1R biological activities in a very large num-
ber of experimental models as well as in clinical settings 
[14, 16, 24, 90, 246–258], has been demonstrated to pro-
duce very limited resistance [22, 259, 260] to anti-IGF-1R 
therapy, and has proven efficacy in clinical trials [261]. The 
remarkable feature of PPP that differentiates it from ATP-
inhibitors is that, similar to anti-IGF-1R antibodies, PPP 
also triggers IGF-1R downregulation [143]. This feature 
deserves special attention because it supports the logical 
but still contentious [90] assumption that receptor down-
regulation is desirable in addition to inhibition of its TK 
activity [15, 95].
Yet, the debate on how important receptor downregula-
tion is in relation to kinase inhibition is hiding a paradox: 
how is the receptor downregulated by inhibiting its kinase 
activity?
The classical, binary ON/OFF model for IGF-1R signal-
ing and degradation implies that the only way to maintain 
the receptor in an ‘OFF’ state is by preventing kinase activ-
ity while degradation would only occur with an ‘ON’ state 
receptor. evidently this model is insufficient, because it 
cannot account for the contradiction that anti-IGF-1R anti-
bodies (or PPP) trigger receptor degradation in the absence 
of kinase activation. This contradiction was recently investi-
gated for the case of anti-IGF-1R antibody (Figitumumab)-
induced receptor degradation [140]. Although the antibod-
ies were primarily designed to block the ligand–receptor 
interaction thus preventing kinase activity, it has been dem-
onstrated that targeting antibodies act as “biased” IGF-1R 
agonists, activating β-arrestin recruitment to the receptor, 
with subsequent receptor ubiquitination, internalization, 
eRK signaling activation, and IGF-1R degradation [140]. 
In agreement with this, anti-IGF-1R therapy efficacy was 
proven to be highly dependent on β-arrestin 1 expression 
and modulated by co-targeting β-arrestin 1-mediated sign-
aling [140]. Notably, a similar mechanism of β-arrestin 
1-mediated receptor ubiquitination and downregulation 
with activation of the β-arrestin 1/eRK second signaling 
wave has also been demonstrated in the case of the PPP 
paradox [143].
The experimental data provided by these studies fully 
substantiate and support the new paradigm for IGF-1R 
signaling which allows for unbalanced signaling and 
kinase activation/receptor downregulation dichotomy 
(Fig. 4). According to this model, the conformation of 
IGF-1R, which activates the kinase cascade, can be dis-
tinct from that which interacts with β-arrestins or other 
signaling molecules. Receptor modification induced by 
ligands, small molecule inhibitors, or intra-cellular inter-
acting proteins can further be interpreted as alterations to 
the IGF-1R conformation, there being more than just two 
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(ON/OFF) conformations. Different conformations can be 
mutually exclusive and can determine the quality, quantity, 
and duration of output signaling from the receptor as well 
as the fate of the receptor (Fig. 4). Recognizing the dual 
role of β-arrestin in controlling receptor downregulation as 
well as kinase-independent signaling, the new model we 
propose (Fig. 4) can accommodate all experimental data, 
demonstrating that IGF-1R signaling is not exclusively 
dependent on its kinase activity and can be activated and 
downregulated in a “biased” manner via β-arrestin 1 by 
IGF-1R inhibitors or by natural “biased” agonists [143, 
253] (Table 2). In the emerging model of IGF-1R signaling, 
the question of “how important receptor is downregulation 
in relation to kinase inhibition?” is getting a new meaning: 
“Is it possible to downregulate the IGF-1R without activat-
ing signaling?” As downregulation without signaling has 
never been recognized, a simpler solution would be to iden-
tify the biased signaling pathways and target them sepa-
rately [140].
Although oversimplified and insufficient to explain sev-
eral outcomes of IGF-1R activation, the classical paradigm 
is currently in use when selecting the agents targeting the 
IGF-1R. The best example is the case of anti-IGF-1R anti-
body: during their development, antibodies were designed 
to achieve the maximum binding to IGF-1R, to compete 
with the natural agonists [140]. In the subsequent drug 
screening for clonal selection, the assays were limited to 
confirmation of their inhibitory effects on IGF-1-induced 
receptor signaling [142, 262–265]. As long as the canoni-
cal IGF-1R model does not acknowledge kinase-independ-
ent signaling, it is not surprising that targeting antibodies 
were rarely evaluated in IGF-1-independent conditions to 
estimate their intrinsic agonistic potential: most measuring 
receptor phosphorylation, a few checking IRS/Akt activa-
tion, and none checking MAPK/eRK activity.
Despite big expectations regarding the use of anti-IGF-
1R for cancer treatment, almost all clinical trials were 
stopped due to futility, whereas some pharmaceutical com-
panies closed their programs for developing IGF-1R inhibi-
tors [93]. Furthermore, the value of IGF-1R as a target for 
cancer therapy has been questioned [90, 93]. while several 
reasons for the failure of the anti-IGF-1R have already 
been discussed in detail [90, 93], the new paradigm we 
propose for the IGF-1R signaling highlights another poten-
tial cause for these unsatisfactory results: biased-signaling 
activation by anti-IGF-1R antibodies. The best example is 
again Figitumumab, designed to prevent the IGF-1 binding 
to its receptor and kinase-dependent signaling. In ewing 
sarcoma, at least two resistance mechanisms have been 
reported, developed after Figitumumab treatment: forma-
tion of the IGF-1R/IR hybrid receptors [266] and biased 
IGF-1R signaling activation [140]. As described before, the 
IGF-1R/IR hybrid formation could be appreciated as a form 
of receptor bias. Challenging the classical two-state model 
in which the antibodies were designed, the new paradigm 
in which a biased-receptor (IGF-1R/IR hybrid) is activated 
by a biased-agonist (Figitumumab) provides an explanation 
as to why such a strategy did not work in clinical settings 
and advocates recognition of IGF-1R as a key target for 
cancer therapy and a clear choice for the baby rather than 
the bathwater [91].
Concluding remarks
Today, targeting the IGF-IR and components of its signal-
ing pathway in different forms of cancer is a major research 
area. Yet, the design of such targeting agents is based 
mostly on the classical ON/OFF model of IGF-1R activa-
tion. The present review highlights the fact that, in addi-
tion to the classical kinase pathway, IGF-1R activity and 
its biological effects are controlled by a variety of adaptor/
signaling-proteins through IGF-1R posttranslational modi-
fications, including tyrosine and serine phosphorylation, 
de-phosphorylation, ubiquitination, and sumoylation. The 
complexity of IGF-1R behavior following exposure to IGF-
1R inhibitors reinforces the need to understand the relation-
ships between different signaling pathways and between 
signaling and degradation. Only this can lead to the rational 
design and testing of IGF-1R inhibitors and the successful 
combining of these therapeutics with others targeting paral-
lel pathways. Searching for therapies inhibiting only IGF-
1R kinase activity may appear to invalidate the IGF-1R as 
a target for cancer therapy, while many potential drugs that 
modify alternative downstream effects, the “biasing ago-
nists”, are not considered.
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